Derivatives of soluble T-4
    9.
    发明授权
    Derivatives of soluble T-4 失效
    可溶性T-4的衍生物

    公开(公告)号:US5110906A

    公开(公告)日:1992-05-05

    申请号:US160348

    申请日:1988-02-24

    摘要: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.

    摘要翻译: 本发明提供能够特异性形成与包含多肽的人免疫缺陷病毒包膜糖蛋白复合物的治疗剂。 在本发明的一个实施方案中,多肽的氨基酸序列包含图1所示的氨基酸序列。 约1 + 1至约+ 18 5的氨基酸序列与约+353至约+ 371融合。 在本发明的另一个实施方案中,多肽的氨基酸序列包含图1所示的氨基酸序列。 与约+353至约+ 371的氨基酸序列融合的约1 + 1至约+ 10 6。 在本发明的另一个实施方案中,多肽的氨基酸序列包含图1所示的氨基酸序列。 6从约+1到约+185。 本发明还提供了治疗感染人免疫缺陷病毒的受试者的方法。 该方法包括向受试者施用有效量的包含有效量的本发明治疗剂和药学上可接受的载体的药物组合物。